

Otitis Media Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/O6F1CA533BC6EN.html>

Date: March 2022

Pages: 64

Price: US\$ 2,000.00 (Single User License)

ID: O6F1CA533BC6EN

Abstracts

Otitis Media Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Otitis Media - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Otitis Media (Ear Nose Throat Disorders) pipeline landscape.

Otitis media (OM) is any inflammation of the middle ear, the air-filled space behind the eardrum that contains the tiny vibrating bones of the ear. Symptoms include ear pain, difficulty sleeping, loss of balance, fever, headache and loss of appetite. Risk factors include age, seasonal factors and exposure to tobacco smoke or high levels of air pollution. Treatment includes antibiotics and antipyrene.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Otitis Media - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Otitis Media (Ear Nose Throat Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and

press releases.

The Otitis Media (Ear Nose Throat Disorders) pipeline guide also reviews of key players involved in therapeutic development for Otitis Media and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Preclinical and Discovery stages are 1, 4, 1, 15 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Otitis Media (Ear Nose Throat Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Otitis Media (Ear Nose Throat Disorders).

The pipeline guide reviews pipeline therapeutics for Otitis Media (Ear Nose Throat Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Otitis Media (Ear Nose Throat Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Otitis Media (Ear Nose Throat Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Otitis Media (Ear Nose Throat Disorders)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Otitis Media (Ear Nose Throat Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Otitis Media (Ear Nose Throat Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand

business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Global Markets Direct Report Coverage

Otitis Media - Overview

Otitis Media - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Otitis Media - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Otitis Media - Companies Involved in Therapeutics Development

Blue Water Vaccines Inc

Ceolia Pharma Co Ltd

Clarametyx Biosciences Inc

Earnano LLC

Furen Pharmaceutical Group Co Ltd

Hunan Sanqing Pharmaceutical Co Ltd

Inventprise LLC

Laboratorios Salvat SA

Maxwell Biosciences Inc

Merck & Co Inc

MerLion Pharmaceuticals Pte Ltd

MyX Therapeutics Inc

NTC srl

O-Ray Pharma Inc

Olymvax Biopharmaceuticals Inc

ProclaRx LLC

Vaxcyte Inc

Vyome Therapeutics Inc

Otitis Media - Drug Profiles

(ciprofloxacin hydrochloride + fluocinolone acetonide) - Drug Profile

Product Description

Mechanism Of Action

History of Events
aspoxicillin - Drug Profile
Product Description
Mechanism Of Action
BWV-201 - Drug Profile
Product Description
Mechanism Of Action
History of Events
CMTX-200 - Drug Profile
Product Description
Mechanism Of Action
CMTX-301 - Drug Profile
Product Description
Mechanism Of Action
Drug for Otitis Media - Drug Profile
Product Description
Mechanism Of Action
Drugs for Otitis Media - Drug Profile
Product Description
Mechanism Of Action
ENT-103 - Drug Profile
Product Description
Mechanism Of Action
History of Events
finafloxacin - Drug Profile
Product Description
Mechanism Of Action
History of Events
IVT-25 - Drug Profile
Product Description
Mechanism Of Action
NTC-011 - Drug Profile
Product Description
Mechanism Of Action
OR-404IT - Drug Profile
Product Description
Mechanism Of Action
History of Events
PCL-1440 - Drug Profile

Product Description

Mechanism Of Action

History of Events

pneumococcal (13-valent) vaccine - Drug Profile

Product Description

Mechanism Of Action

pneumococcal (23-valent) vaccine - Drug Profile

Product Description

Mechanism Of Action

pneumococcal polysaccharide [15-valent] vaccine - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules for Chronic Suppurative Otitis Media (CSOM) - Drug Profile

Product Description

Mechanism Of Action

History of Events

solithromycin - Drug Profile

Product Description

Mechanism Of Action

History of Events

tebipenem pivoxil - Drug Profile

Product Description

Mechanism Of Action

Vaccine for Otitis Media - Drug Profile

Product Description

Mechanism Of Action

VAX-24 - Drug Profile

Product Description

Mechanism Of Action

VAX-XP - Drug Profile

Product Description

Mechanism Of Action

VT-1917 - Drug Profile

Product Description

Mechanism Of Action

Otitis Media - Dormant Projects

Otitis Media - Discontinued Products

Otitis Media - Product Development Milestones

Featured News & Press Releases

Dec 20, 2021: Clarametyx Biosciences awarded \$3.15 million grant from NIH to advance a broad-spectrum vaccine technology for bacterial infections

Oct 04, 2021: Lee's Pharmaceutical Holdings: Voluntary announcement - Update on the commercialisation and research and development of Cetraxal Plus of the group

Sep 01, 2021: NanoCarrier : Accomplishment of primary endpoint in phase III clinical study of ENT103

May 31, 2021: NanoCarrier : Completion of patient enrollment for phase III trial with ENT103

Jan 13, 2021: Lee's Pharmaceutical Holdings: Voluntary announcement update on an investigational ear drug product

Jun 02, 2017: Eight Presentations at ASM Microbe Include Late Breaker From Cempra's Phase 3 Fusidic Acid Study and Solithromycin Data on Gonorrhoea and Otitis Media

May 18, 2017: Pediapharm Announces the Commercial Launch of Otixal in Canada

Dec 27, 2016: OTOVEL's trials published in JAMA

Dec 12, 2016: Pediapharm receives Health Canada approval for Otixal

Sep 29, 2014: SALVAT announces positive top-line results from two Phase III studies of its novel otic antibiotic/steroid combination solution in the treatment of AOMT with Tympanostomy tubes

May 28, 2013: Salvat Completes Enrollment Of Phase III Study For New Combination In Acute Otitis Media In Pediatric Patients With Tympanostomy Tubes

Apr 18, 2012: MerLion Initiates Phase III Clinical Program To Evaluate Finafloxacin For Treatment Of Acute Otitis Media

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Otitis Media, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Otitis Media - Pipeline by Blue Water Vaccines Inc, 2022
Otitis Media - Pipeline by Ceolia Pharma Co Ltd, 2022
Otitis Media - Pipeline by Clarametyx Biosciences Inc, 2022
Otitis Media - Pipeline by Earnano LLC, 2022
Otitis Media - Pipeline by Furen Pharmaceutical Group Co Ltd, 2022
Otitis Media - Pipeline by Hunan Sanqing Pharmaceutical Co Ltd, 2022
Otitis Media - Pipeline by Inventprise LLC, 2022
Otitis Media - Pipeline by Laboratorios Salvat SA, 2022
Otitis Media - Pipeline by Maxwell Biosciences Inc, 2022
Otitis Media - Pipeline by Merck & Co Inc, 2022
Otitis Media - Pipeline by MerLion Pharmaceuticals Pte Ltd, 2022
Otitis Media - Pipeline by MyX Therapeutics Inc, 2022
Otitis Media - Pipeline by NTC srl, 2022
Otitis Media - Pipeline by O-Ray Pharma Inc, 2022
Otitis Media - Pipeline by Olymvax Biopharmaceuticals Inc, 2022
Otitis Media - Pipeline by ProclaRx LLC, 2022
Otitis Media - Pipeline by Vaxcyte Inc, 2022
Otitis Media - Pipeline by Vyome Therapeutics Inc, 2022
Otitis Media - Dormant Projects, 2022
Otitis Media - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Otitis Media, 2022

Number of Products under Development by Companies, 2022

Number of Products by Targets, 2022

Number of Products by Stage and Targets, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

I would like to order

Product name: Otitis Media Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/O6F1CA533BC6EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/O6F1CA533BC6EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

